📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
2 articles
AVG GRADE
HIGH
score: 0.75
SENTIMENT
BULLISH
TOTAL VIEWS
57
HROW Latest News & AI Sentiment Analysis
2 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 3 ARTICLES
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Harrow has secured exclusive global rights to TYRVAYA®, a first-mover FDA-approved nasal spray for dry eye disease, through acquisition...
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Harrow (HROW) presented three clinical studies at the ASRS 2026 Annual Meeting supporting its retina portfolio, specifically IHEEZO®...
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow Health (HROW) announced commercial availability of BYOOVIZ®, a ranibizumab biosimilar targeting retinal disease treatment in the...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice